Eisai now expects Leqembi sales to total JPY 42.5 billion (approximately SEK 3 billion) for the period, down from JPY 56.5 billion announced in May.

--BioArctic AB's partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion for their fiscal year 2025, corresponding to a 73 percent growth compared to the previous year.

Eisai Co., Ltd. (OTCPK:ESALF) has reported annual figures. The forecasts are pretty good for Leqembi, absolutely in line with our expectations for considerable growth. We believe they far exceed ...

Patients who started Leqembi early continued to benefit from the drug over three years, showing a slower rate of cognitive decline compared to the other two groups, according to an Eisai presentation.

Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion. Nov. 07, 2024 11:19 PM ET Barnes Group Inc. (B), BIOA.

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...